Abraham Hartzema, PharmD, MSPH, PhD
Professor and Eminent Scholar, Perry A. Foote Chair in Health Outcomes and Pharmacoeconomics
University of Florida
Dr. Hartzema investigates health outcomes with an emphasis on pharmacoepidemiology, passive and active drug safety surveillance systems, therapeutic risk management, and program evaluation. He has served as principal and co-investigator on major grants from the National Institutes of Health, government entities, foundations and the pharmaceutical industry. He has co-authored and edited three books, two of which are in multiple editions, two monographs, one of which is translated in several languages, and has published and presented more than 100 chapters, journal articles, abstracts and presentations. He has served on the Scientific Board of the International Pharmaceutical Federation, and serves or served on eight editorial boards. He is the recipient of the 2007 UF Foundation research Award. He is an elected Fellow of the International Society for Pharmacoepidemiology. In 2008-2009, he spent his sabbatical in the Immediate Office of the Food and Drug Administration’s Commissioner working on the Sentinel system.
Boyce RD, Ryan PB, Noren GN, et al. Bridging Islands of Information to Establish an Integrated Knowledge Base of Drugs and Health Outcomes of Interest. Drug Saf. 2014 Jul 2;2:2.
Madigan D, Stang PE, Berlin JA, et al. A Systematic Statistical Approach to Evaluating Evidence from Observational Studies. Annual Review of Statistics and Its Application. 2014;1(1):11-39.
Stang P, Ryan P, Hartzema AG, et al. Development and Evaluation of Infrastructure and Analytic Methods for Systematic Drug Safety Surveillance: Lessons and Resources from the Observational Medical Outcomes Partnership. In: Elizabeth B. Andrews NM, editor. Mann’s Pharmacovigilance. Third ed: Wiley-Blackwell; 2014. p. 866.
Ryan PB, Stang PE, Overhage JM, et al. A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 2013 Oct;36(Suppl 1):S143-58. doi: 10.1007/s40264-013-0108-9.
Hartzema AG, Reich CG, Ryan PB, et al. Managing data quality for a drug safety surveillance system. Drug Saf. 2013 Oct;36(Suppl 1):S49-58. doi: 10.1007/s40264-013-0098-7.
Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013 Oct;36(Suppl 1):S33-47. doi: 10.1007/s40264-013-0097-8.
Stang PE, Ryan PB, Overhage JM, Schuemie MJ, Hartzema AG, Welebob E. Variation in choice of study design: findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) survey. Drug Saf. 2013 Oct;36(Suppl 1):S15-25. doi: 10.1007/s40264-013-0103-1.
Madigan D, Ryan PB, Schuemie M, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013 Aug 15;178(4):645-51. doi: 10.1093/aje/kwt010. Epub 2013 May 5.
Ryan PB, Madigan D, Stang PE, Marc Overhage J, Racoosin JA, Hartzema AG. Response to comment on ’empirical assessment of methods for risk identification in healthcare data’. Stat Med. 2013 Mar 15;32(6):1075-7. doi: 10.02/sim.5725.
Ryan PB, Madigan D, Stang PE, Overhage JM, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012 Dec 30;31(30):4401-15. doi: 10.1002/sim.5620. Epub 2012 Sep 27.
Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012 Jan-Feb;19(1):54-60. doi: 10.1136/amiajnl-2011-000376. Epub 2011 Oct 28.
Stang PE, Ryan PB, Dusetzina SB, et al. Health Outcomes of Interest in Observational Data: Issues in Identifying Definitions in the Literature. Health Outcomes Research in Medicine. 2012 2//;3(1):e37-e44.
Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010 Nov 2;153(9):600-6. doi: 10.7326/0003-4819-153-9-201011020-00010.
Ryan P, Welebob E, Hartzema A, Stang P, Overhage JM. Surveying US Observational Data Sources and Characteristics for Drug Safety Needs. Pharm Med. 2010 2010/08/01;24(4):231-8.